This is a paid press release. Contact the press release distributor directly with any inquiries.
The Joint Corp. Reports Third Quarter 2026 Financial Results
– Revenue Increases to $13.6 Million –
– Net Income from Continuing Operations Increases by $1.2 Million to $1.5 Million and Adjusted EBITDA From Continuing Operations Increases by $0.9 Million to $2.3 Million –
–Continued Execution on Capital Allocation Priorities with Regional Developer Territory Buybacks and $3.8 Million in Stock Repurchases –
– Board of Directors Authorizes an Additional $5.0 Million for Stock Repurchases –
SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), the nation’s largest franchisor of chiropractic care through The Joint Chiropractic® network, today reported financial results for the third quarter ended September 30, 2026. The following figures represent continuing operations unless otherwise stated. The Company also updated its full year 2026 guidance (see details below).
Third Quarter 2026 Financial Highlights
-
Revenues grew to $13.6 million, up 1% compared to the third quarter of 2025.
-
System-wide sales1 were $123.3 million, a 3.1% decrease compared to the third quarter of 2025.
-
Reported comp sales2 of (1.9)%, compared to (2.8)% in the second quarter of 2026.
-
Net loss from consolidated operations was $117,000, compared to net income from consolidated operations of $855,000 in the third quarter of 2025. Net income from continuing operations was $1.5 million, compared to net income from continuing operations of $290,000 in the third quarter of 2025.
-
Adjusted EBITDA (a non-GAAP metric) from consolidated operations was $3.3 million, in line with $3.3 million in the third quarter of 2025. Adjusted EBITDA from continuing operations was $2.3 million, compared to $1.4 million in the third quarter of 2025.
-
Cash flow used in operating activities was $128,000, compared to cash provided by operating activities of $1.8 million in the third quarter of 2025, and free cash flow (a non-GAAP metric) was $(509,000), compared to $1.5 million in the third quarter of 2025.
-
Repurchased 461,000 shares for total consideration of approximately $3.8 million at an average of $8.30 per share during the third quarter.
Third Quarter 2026 and Recent Operating Highlights
-
On October 1, 2026, the Company reacquired the regional developer (“RD”) rights for Texas, a region consisting of 141 franchised clinics, for total cash consideration of $8.0 million due at closing and up to $2.0 million in potential additional consideration payments if certain gross sales metrics are met or exceeded in the Texas region during the two annual periods following the closing.
-
Year to date in 2026, the Company has reacquired the RD rights to five territories, including Texas, consisting of 189 franchised clinics. These efforts will lead to the realization of approximately $3.0 million in reduced RD royalties on an annualized basis, with approximately one-third of this benefit being offset by internal costs to manage these territories.
-
-
Total clinic count was 930 at September 30, 2026.
-
Opened four clinics, closed 15 clinics, and refranchised 26 clinics during the quarter, for a total of 915 franchised clinics and 15 company-owned or managed clinics at September 30, 2026.
-
